What is Ultragenyx Pharmaceutical Inc.'s Market Cap?

Ultragenyx Pharmaceutical Inc.'s Market Cap is $1.5B, based on as-reported figures from SEC (XBRL) filings.

What is Ultragenyx Pharmaceutical Inc.'s Price / Sales?

Ultragenyx Pharmaceutical Inc.'s Price / Sales is 2.0×, based on as-reported figures from SEC (XBRL) filings.

What is Ultragenyx Pharmaceutical Inc.'s Revenue (TTM)?

Ultragenyx Pharmaceutical Inc.'s Revenue (TTM) is $717.0M, based on as-reported figures from SEC (XBRL) filings.

What is Ultragenyx Pharmaceutical Inc.'s Net Income (TTM)?

Ultragenyx Pharmaceutical Inc.'s Net Income (TTM) is -$586.0M, based on as-reported figures from SEC (XBRL) filings.

What is Ultragenyx Pharmaceutical Inc.'s EBITDA?

Ultragenyx Pharmaceutical Inc.'s EBITDA is -$495.0M, based on as-reported figures from SEC (XBRL) filings.

What is Ultragenyx Pharmaceutical Inc.'s Diluted EPS (TTM)?

Ultragenyx Pharmaceutical Inc.'s Diluted EPS (TTM) is -5.94, based on as-reported figures from SEC (XBRL) filings.

What is Ultragenyx Pharmaceutical Inc.'s EBITDA Margin?

Ultragenyx Pharmaceutical Inc.'s EBITDA Margin is -69.0%, based on as-reported figures from SEC (XBRL) filings.

Ultragenyx Pharmaceutical Inc. (RARE) Financial Statements

Ultragenyx Pharmaceutical Inc.

SIC 2834 · PHARMACEUTICAL PREPARATIONS

FIGI BBG001V2MJJ2

XNAS · usd

14.88▼ 0.42 (-2.75%)

As of 2026-09-08

Valuation

Market Cap

Enterprise Value—

Trailing P/E—

Price / Sales

EV / Revenue—

EV / EBITDA—

Financial Highlights

Revenue (TTM)

Net Income (TTM)

EBITDA

Diluted EPS (TTM)

EBITDA Margin

Net Debt—

Trading Information

Previous Close15.30

Day's Range14.63 – 15.25

52-Week Range13.81 – 39.89

Volume5.9M

Avg Volume3.4M

Share Statistics

Shares Outstanding

Employees1,371

ExchangeXNAS

Listed2014-01-31

Share count as of July 31, 2026

ViewDetail

Period

Loading Income Statement…

Key questions about Ultragenyx Pharmaceutical Inc. (RARE)

What is Ultragenyx Pharmaceutical Inc.'s Market Cap?: Ultragenyx Pharmaceutical Inc.'s Market Cap is $1.5B, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Price / Sales?: Ultragenyx Pharmaceutical Inc.'s Price / Sales is 2.0×, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Revenue (TTM)?: Ultragenyx Pharmaceutical Inc.'s Revenue (TTM) is $717.0M, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Net Income (TTM)?: Ultragenyx Pharmaceutical Inc.'s Net Income (TTM) is -$586.0M, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s EBITDA?: Ultragenyx Pharmaceutical Inc.'s EBITDA is -$495.0M, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s Diluted EPS (TTM)?: Ultragenyx Pharmaceutical Inc.'s Diluted EPS (TTM) is -5.94, based on as-reported figures from SEC (XBRL) filings.
What is Ultragenyx Pharmaceutical Inc.'s EBITDA Margin?: Ultragenyx Pharmaceutical Inc.'s EBITDA Margin is -69.0%, based on as-reported figures from SEC (XBRL) filings.